4′-Fluorouridine is an oral antiviral that blocks respiratory syncytial virus and SARS-CoV-2 replication

Author:

Sourimant Julien1ORCID,Lieber Carolin M.1,Aggarwal Megha1,Cox Robert M.1,Wolf Josef D.1ORCID,Yoon Jeong-Joong1ORCID,Toots Mart1,Ye Chengin2ORCID,Sticher Zachary3ORCID,Kolykhalov Alexander A.34,Martinez-Sobrido Luis2ORCID,Bluemling Gregory R.34ORCID,Natchus Michael G.3,Painter George R.345ORCID,Plemper Richard K.16ORCID

Affiliation:

1. Center for Translational Antiviral Research, Georgia State University, Atlanta, GA 30303, USA.

2. Texas Biomedical Research Institute, San Antonio, TX 78227, USA.

3. Emory Institute for Drug Development, Emory University, Atlanta, GA 30322, USA.

4. Drug Innovation Ventures at Emory (DRIVE), Atlanta, GA 30322, USA.

5. Department of Pharmacology, Emory University School of Medicine, Atlanta, GA 30322, USA.

6. Department of Pediatrics, Emory University School of Medicine, Atlanta, GA 30322, USA.

Abstract

Preparing antiviral defenses Antiviral drugs are an important tool in the battle against COVID-19. Both remdesivir and molnupiravir, which target the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) polymerase, were first developed against other RNA viruses. This highlights the importance of broad-spectrum antivirals that can be rapidly deployed against related emerging pathogens. Sourimant et al . used respiratory syncytial virus (RSV) as a primary indication in identifying further drugs that target the polymerase enzyme of RNA viruses. The authors explored derivatives of molnupiravir and identified 4′ fluorouridine (EIDD-2749) as an inhibitor of the polymerase of RSV and SARS-CoV-2. This drug can be delivered orally and was effective against RSV in mice and SARS-CoV-2 in ferrets. —VV

Publisher

American Association for the Advancement of Science (AAAS)

Subject

Multidisciplinary

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3